AirDuo RespiClick (fluticasone propionate and salmeterol inhalation powder) and ArmonAir
RespiClick (fluticasone propionate inhalation powder) have been approved by the FDA for …

Abstract Wixela® Inhub® is the first therapeutically equivalent, substitutable generic version
of Advair Diskus®(fluticasone propionate/salmeterol) approved for the treatment of asthma …

The novel, easy-to-use, breath-actuated fluticasone propionate/salmeterol multidose dry
powder inhaler (MDPI)(AirDuo RespiClick®) was recently approved in the USA for twice …

Both asthma and chronic obstructive pulmonary disease (COPD) are inflammatory chronic
respiratory conditions with high rates of morbidity and mortality worldwide. The objectives of …

Background: Wixela® Inhub® is a dry powder inhaler approved as a generic equivalent to
Advair® Diskus®(fluticasone propionate [FP]/salmeterol fixed-dose combination) for patients …

Fluticasone furoate/vilanterol [Relvar®, Revinty®(EU); Breo®(USA)], a fixed-dose
combination of an inhaled corticosteroid (ICS) and a long-acting β2-adrenoreceptor agonist …

Rationale: inhalation. The efficacy, pharmacokinetics (PK), and safety of 4 different doses of
fluticasone propionate (Fp) MDPI versus placebo MDPI and Fp Diskus (GlaxoSmithKline …

This study evaluated efficacy and safety of an innovative dry powder inhaler (DPI–Sandoz)
vs Seretide™ Accuhaler™(GSK) containing 50 μg salmeterol and 100 μg fluticasone per …

Introduction: Incorrect use of inhaler devices by patients with asthma is common and can
adversely affect clinical outcomes. Devices that are straightforward to use are less likely to …

Introduction and objectives Guideline-defined asthma control may be achieved and
maintained in the majority of patients by treatment with a combination of a corticosteroid and …